Objective:

To evaluate the effectiveness of ctDNA monitoring in predicting relapse and survival outcomes in early breast cancer patients compared to standard treatment response measures.

Key Findings:

• Persistence of ctDNA after neoadjuvant therapy was strongly associated with recurrence and death.
• Patients with cleared ctDNA during treatment had significantly better outcomes.
• ctDNA dynamics were more prognostic than pathologic complete response.
• ctDNA detection often preceded clinical relapse by a median of 13.8 months.

Interpretation:

Limitations:

Conclusion: